Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases

被引：12

作者：

Cheng, Pin-Nan ^{[1
]}

Chen, Wen-Jone ^{[2
,3
]}

Hou, Charles Jia-Yin ^{[4
]}

Lin, Chih-Lin ^{[5
]}

Chang, Ming-Ling ^{[6
,7
]}

Wang, Chia-Chi ^{[8
,9
]}

Chang, Wei-Ting ^{[10
,11
,12
,13
]}

Wang, Chao-Yung ^{[14
,15
,16
]}

Lin, Chun-Yen ^{[17
,18
]}

Hung, Chung-Lieh ^{[19
,20
]}

Peng, Cheng-Yuan ^{[21
,22
]}

Yu, Ming-Lung ^{[11
,12
,13
,23
,24
,25
,26
]}

Chao, Ting-Hsing ^{[1
]}

Huang, Jee-Fu ^{[23
]}

Huang, Yi-Hsiang ^{[27
,28
,29
]}

Chen, Chi-Yi ^{[30
]}

Chiang, Chern-En ^{[31
,32
,33
]}

Lin, Han-Chieh ^{[28
]}

Li, Yi-Heng ^{[1
]}

Lin, Tsung-Hsie ^{[34
,35
,36
]}

Kao, Jia-Horng ^{[37
]}

Wang, Tzung-Dau ^{[4
,38
]}

Liu, Ping-Yen ^{[1
]}

Wu, Yen-Wen ^{[39
,40
,41
,42
]}

Liu, Chun-Jen ^{[43
,44
]}

机构：

[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan

[2] Min Sheng Gen Hosp, Dept Internal Med, Taoyuan, Taiwan

[3] Natl Taiwan Univ Hosp, Cardiovasc Ctr, Taipei, Taiwan

[4] MacKay Mem Hosp, Cardiovasc Ctr, Taipei, Taiwan

[5] Taipei City Hosp, Renai Branch, Dept Gastroenterol, Taipei, Taiwan

[6] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Gastroenterol & Hepatol, Div Hepatol, Taoyuan, Taiwan

[7] Chang Gung Univ, Coll Med, Dept Med, Taoyuan, Taiwan

[8] Tzu Chi Univ, Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Gastroenterol, Hualien, Taiwan

[9] Tzu Chi Univ, Sch Med, Hualien, Taiwan

[10] Chi Mei Med Ctr, Dept Internal Med, Div Cardiol, Tainan, Taiwan

[11] Natl Sun Yat Sen Univ, Coll Med, Kaohsiung, Taiwan

[12] Natl Sun Yat sen Univ, Coll Med, Doctoral Program Clin & Expt Med, Kaohsiung, Taiwan

[13] Natl Sun Yat sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis, Kaohsiung, Taiwan

[14] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Cardiol, Taoyuan City, Taiwan

[15] Chang Gung Univ, Coll Med, Sch Med, Taoyuan City, Taiwan

[16] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan, Taiwan

[17] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Gastroenterol & Hepatol, Taoyuan, Taiwan

[18] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[19] MacKay Med Coll, Inst Biomed Sci, New Taipei City, Taiwan

[20] Mackay Mem Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan

[21] China Med Univ Hosp, Ctr Digest Med, Taichung, Taiwan

[22] China Med Univ, Sch Chinese Med, Taichung, Taiwan

[23] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Div, Dept Internal Med, Kaohsiung, Taiwan

[24] Kaohsiung Med Univ, Coll Med, Kaohsiung, Taiwan

[25] Kaohsiung Med Univ, Ctr Liquid Biopsy & Cohort Res, Kaohsiung, Taiwan

[26] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan

[27] Taipei Vet Gen Hosp, Healthcare & Serv Ctr, Taipei, Taiwan

[28] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan

[29] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Coll Med, Taipei, Taiwan

[30] Ditmanson Med Fdn Chiayi Christian Hosp, Dept Internal Med, Chiayi, Taiwan

[31] Taipei Vet Gen Hosp, Gen Clin Res Ctr, Taipei, Taiwan

[32] Taipei Vet Gen Hosp, Cardiovasc Ctr, Taipei, Taiwan

[33] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan

[34] Kaohsiung Med Univ Hosp, Div Cardiol, Dept Internal Med, Kaohsiung, Taiwan

[35] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan

[36] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan

[37] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan

[38] MacKay Med Coll, New Taipei City, Taiwan

[39] Far Eastern Mem Hosp, Div Cardiol, Cardiovasc Med Ctr, 21,Sect 2,Nanya S Rd, New Taipei City 220, Taiwan

[40] Far Eastern Mem Hosp, Dept Nucl Med, New Taipei City, Taiwan

[41] Natl Yang Ming Chao Tung Univ, Sch Med, Taipei, Taiwan

[42] Yuan Ze Univ, Grad Inst Med, Taoyuan City, Taiwan

[43] Natl Taiwan Univ Hosp, Dept Internal Med, Coll Med & Hosp, Hepatitis Res Ctr, 1 Changde St, Taipei 100229, Taiwan

[44] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med & Hosp, 1 Changde St, Taipei 100229, Taiwan

来源：

CLINICAL AND MOLECULAR HEPATOLOGY | 2024年 / 30卷 / 01期

关键词：

MAFLD; Cardiovascular disease; Position statement; Taiwan; CLINICAL-PRACTICE GUIDELINES; TYPE-2; DIABETES-MELLITUS; LONG-TERM MORTALITY; NONALCOHOLIC STEATOHEPATITIS; VITAMIN-E; RESISTANCE EXERCISE; HEPATIC STEATOSIS; PRACTICE GUIDANCE; OBETICHOLIC ACID; IV INHIBITORS;

D O I：

10.3350/cmh.2023.0315

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD. (Clin Mol Hepatol 2024;30:16-36)

引用

页码：16 / 36

页数：22

共 206 条

[1] Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
Akuta, Norio
Kawamura, Yusuke
Watanabe, Chizuru
Nishimura, Akihiro
Okubo, Minoru
Mori, Yasumichi
Fujiyama, Shunichiro
Sezaki, Hitomi
Hosaka, Tetsuya
Kobayashi, Masahiro
Kobayashi, Mariko
Saitoh, Satoshi
Suzuki, Fumitaka
Suzuki, Yoshiyuki
Arase, Yasuji
Ikeda, Kenji
Kumada, Hiromitsu
[J]. HEPATOLOGY RESEARCH, 2019, 49 (05) : 531 - 539
[2] In-Hospital Outcomes of Patients With Non-Alcoholic Fatty Liver Disease Who Underwent Percutaneous Coronary Intervention: A Nationwide Inpatient Sample Analysis
Ali, Hasan
Kazmi, Maryam
Choi, Catherine
Hashemipour, Reza
Singh, Inderjit
Pyrsopoulos, Nikolaos T.
[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
[3] Alkhouri N, 2012, HEPATOLOGY, V55, P331, DOI [10.1002/hep.24721, 10.1002/hep.24767]
[4] Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Ampuero, Javier
Aller, Rocio
Gallego-Duran, Rocio
Crespo, Javier
Luis Calleja, Jose
Garcia-Monzon, Carmelo
Gomez-Camarero, Judith
Caballeria, Joan
Lo Iacono, Oreste
Ibanez, Luis
Garcia-Samaniego, Javier
Albillos, Agustin
Frances, Ruben
Fernandez-Rodriguez, Conrado
Diago, Moises
Soriano, German
Andrade, Raul J.
Latorre, Raquel
Jorquera, Francisco
Morillas, Rosa Maria
Escudero, Desamparados
Estevez, Pamela
Hernandez Guerra, Manuel
Augustin, Salvador
Banales, Jesus M.
Aspichueta, Patricia
Benlloch, Salvador
Miguel Rosales, Jose
Salmeron, Javier
Turnes, Juan
Romero-Gomez, Manuel
[J]. JOURNAL OF HEPATOLOGY, 2020, 73 (01) : 17 - 25
[5] Long-Term Mortality in Nonalcoholic Fatty Liver Disease: Is Liver Histology of Any Prognostic Significance?
Angulo, Paul
[J]. HEPATOLOGY, 2010, 51 (02) : 373 - 375
[6] Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Anstee, Quentin M.
Castera, Laurent
Loomba, Rohit
[J]. JOURNAL OF HEPATOLOGY, 2022, 76 (06) : 1362 - 1378
[7] Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Quentin M.
Targher, Giovanni
Day, Christopher P.
[J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) : 330 - 344
[8] Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis
Antraco, Vitor Jaco
Hirata, Bruna Kelly Sousa
de Jesus Simao, Jussara
Cruz, Maysa Mariana
da Silva, Viviane Simoes
da Cunha de Sa, Roberta Dourado Cavalcante
Abdala, Fernanda Miranda
Armelin-Correa, Lucia
Alonso-Vale, Maria Isabel Cardoso
[J]. NUTRIENTS, 2021, 13 (02) : 1 - 20
[9] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Armstrong, Matthew James
Gaunt, Piers
Aithal, Guruprasad P.
Barton, Darren
Hull, Diana
Parker, Richard
Hazlehurst, Jonathan M.
Guo, Kathy
Abouda, George
Aldersley, Mark A.
Stocken, Deborah
Gough, Stephen C.
Tomlinson, Jeremy W.
Brown, Rachel M.
Huebscher, Stefan G.
Newsome, Philip N.
[J]. LANCET, 2016, 387 (10019) : 679 - 690
[10] The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Avogaro, Angelo
Fadini, Gian Paolo
[J]. DIABETES CARE, 2014, 37 (10) : 2884 - 2894

← 1 2 3 4 5 6 7 8 9 10 →